BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
POSTECH and ImmunoBiome researchers uncover a novel microbiota-Tfh cell axis to enhance antibody production and mucosal ...
OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果